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John Newsom-Davis was born in 1932 and died, aged 74, in 2007. After national service in the Royal Air Force, he read Natural
Sciences at Cambridge. Following clinical studies at the Middlesex Hospital, he began research into respiratory neurophysiology
with Tom Sears at the National Hospital, Queen Square, in London, and spent 1 year with Fred Plum at Cornell University in
New York. After neurology specialist training at Queen Square, he became the director of the Batten Unit, continuing his interest
in respiratory physiology. There he began to work on myasthenia gravis in collaboration with Ricardo Miledi at University
College London and in 1978, after performing the ﬁrst studies on plasma exchange in that disease, he established a myasthenia
gravis research group at the Royal Free Hospital. There he investigated the role of the thymus in this disease and demonstrated
an autoimmune basis for the Lambert Eaton myasthenic syndrome and ‘seronegative’ myasthenia. He was awarded the ﬁrst
Medical Research Council Clinical Research Professorship in 1979 but moved to Oxford in 1987 when he was elected Action
Research Professor of Neurology. While at Oxford, he continued to run a very successful multidisciplinary group, researched
further into the thymic abnormalities and cellular immunology of myasthenia, identiﬁed antibody-mediated mechanisms in
acquired neuromyotonia, and began the molecular work that identiﬁed the genetic basis for many forms of congenital myasthe-
nic syndrome. Meanwhile, he was also involved in university and college governance and contributed widely to the Medical
Research Council, government committees, research charities and the Association of British Neurologists. Among many honours,
he was elected Fellow of the Royal Society in 1991, appointed Commander of the British Empire in 1996 and made a Foreign
Associate Member of the Institute of Medicine of the United States in 2001. Nearing and following retirement from Oxford,
where he continued to see patients with myasthenia, he was the President of the Association of British Neurologists and Editor
of Brain, and led a National Institutes of Health-funded international trial of thymectomy.
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Abbreviations: AChR = acetylcholine receptor; ANA = American Neurological Association; CMS = congenital myasthenic syndrome;
HLA = human leukocyte antigen; JND = John Newsom-Davis; MRC = Medical Research Council
Introduction
On a trip to Romania in August 2007, after visiting patients with
myasthenia gravis in Bucharest, John Newsom-Davis (JND, as he
was widely known) was involved in a fatal road accident.
This review of his life and work is based on the many tributes
and obituaries that followed, JND’s interview for the American
Neurological Association (ANA) in 2003, personal knowledge of
his work and contributions from many distinguished colleagues.
His curriculum vitae, publications (Supplementary material B),
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Early years, clinical training,
Queen Square and the Royal
Free Hospital
JND was born in Harpenden, Hertfordshire, UK, to John Kenneth
and Dorothy Eileen Newsom Davis on 18 October 1932, older by
10min than his twin sister Julia. The twins and their younger
sister, Anthea, had a rather conventional middle-class upbringing
with nannies and long walks every afternoon. He was sent to
boarding school at the age of 7 years which, as a quiet and
thoughtful child, he disliked intensely. At 13 years, he went on
to Sherborne School, where he developed prowess in tennis and
hockey, and from where he gained a place at Pembroke College
Cambridge, initially to read English but changing subsequently to
Natural Sciences (Supplementary material C). Though he did not
see much of their father during the war, JND likely inherited his
self-discipline, focus and social awareness from his father who, as
managing director of the Davis Gas Cooker Company (subse-
quently New World Cookers), was also a prominent member of
the Industrial Welfare Society and popular with his workers. JND’s
love of music came from both parents and his love of literature,
poetry, cooking and gentleness from his mother (Supplementary
material D).
JND was a member of a privileged group of 45 national service
men called up in 1951 who, because of the Korean War, were
offered full pilot training in the RAF during their 2 years’ service.
They obtained their ‘Wings’ at RAF Pershore in October 1953
(Fig. 1A). This was probably JND’s ﬁrst opportunity to show his
ability to get on with people of different backgrounds—a gift that
was clearly apparent, and much appreciated, throughout his
career. In the early 1990s, retired British Overseas Airways
Corporation Commander Dayne Markham managed to trace
most of the 45 men and subsequently JND retained contact
with his former colleagues who appreciated his unpretentious
nature and interest in their lives (Supplementary material E).
At Cambridge, JND worked reasonably hard but also enjoyed
university life, becoming Captain of his College hockey team, and
socializing—but not particularly with the medics. During his clinical
training at the Middlesex Hospital, he continued to play hockey
and tennis and made frequent visits to the theatre, concerts and to
the opera, with a wide and varied circle of friends (Supplementary
materials C and D).
He qualiﬁed as a doctor in 1960 and, after house jobs, worked
for Moran Campbell (Fig. 2A) who was very active in respiratory
physiology. JND was also highly inﬂuenced by neurologists
Michael Kremer (Middlesex Hospital) and Roger Gilliatt
(National Hospital, Queen Square and Middlesex Hospital); to-
gether these two interests were the forerunners of his future
clinical research in myasthenia. Campbell provided an introduc-
tion to neurophysiologist, Tom Sears (Fig. 2B), at the National
Hospital, and JND and Sears worked very successfully together
for several years. He won the Queen Square Prize in 1965 and
was awarded an MD by Cambridge University in 1966, after
which he was appointed to the National Hospital as a House
Physician followed by University Lecturer (Fig. 3). Throughout
this period he kept up his research interests, co-authoring with
Moran Campbell and Emilio Agostoni The Respiratory Muscles:
Mechanics and Neural Control in 1970—a prestigious publication
for a doctor in training (Supplementary material F for the fate of
one copy). In 1969, JND, newly married and accompanied by his
wife, Rosemary (Fig. 1B), ﬂew off to spend a year with Fred
Plum in New York. On his return, he became a consultant neur-
ologist at the National Hospital and took up the study of human
intercostal muscle spindles. It was this preparation that led him
to myasthenia gravis. ‘My friend, Professor Ricardo Miledi, after
distancing himself for many years from human based research,
phoned to ask if I knew anyone carrying out intercostal
muscle biopsies. I said “I do and it so happens he is by my
side”. They got together soon after and the rest is history’
(Tom Sears, Emeritus Professor of Neurophysiology, King’s
College London).
Figure 1 (A) ‘Wings’ at Pershore, aged 21 years in 1953; (B) Engagement to Rosemary in 1963.
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established an independent myasthenia gravis group in Peter
(P.K.) Thomas’ clinical neurosciences department at the Royal
Free Hospital (Asbury, 2011). This also broke the continuity of
his working relationship with Sears but there was no doubt that
his time with Sears was greatly valued (ANA; Supplementary ma-
terial C). As will be described in detail below, the Royal Free
Hospital myasthenia gravis group grew rapidly; the ﬁrst experi-
ments were performed on the requisitioned coffee table but by
1985, generously encouraged by P.K. and his team, and largely
supported by the award of two large Medical Research Council
(MRC) Programme Grants (1979–84; 1984–99), the core team
was formed, research assistants, students and the ﬁrst tranche of
visiting clinical fellows taken on, and about two-thirds of the lab
space in PK’s department devoted to myasthenia research.
University of Oxford,
1987–2007
In the mid-1980s, JND was asked whether he would be interested
in succeeding Brian Matthews as Professor of Clinical Neurology in
Oxford. As Professor Sir David Weatherall recalls:
‘One might wonder why he should have wished to move at
this stage, since by this time he had been appointed MRC
Clinical Research Professor of Neurology and had obtained
two MRC programme grants. He had also gathered together
a diverse and talented research team and the clinical environ-
ment at Queen Square, where he continued to see patients,
was excellent. The question posed for Oxford, therefore,
Figure 3 Queen Square c. 1964. JND is second from the left standing, PK Thomas is ﬁrst and Roger Gilliatt third from the left in the front
row.
Figure 2 (A) With Moran Campbell at a CIBA symposium in 1969. (B) Tom Sears (date unknown).
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vironment. The temptation was the Institute of Molecular
Medicine’.
In 1979, the MRC had established a Molecular Haematology Unit
in Oxford directed by David Weatherall, reﬂecting the increasing
role of molecular and cell biology for the investigation of inherited
blood diseases. It was apparent that the techniques used would
have wide implications across medicine, and there was a need to
train young clinicians in these methods, and provide an ideal envir-
onment for clinically orientated basic scientists to work. David
Weatherall attracted further MRC and other funding to create the
Institute of Molecular Medicine and wanted to include neuroscience
in this multidisciplinary institute. ‘At ﬁrst, John was quite reluctant
to leave London but at a chance meeting at a research policy meet-
ing at Leeds Castle, JND became convinced of the opportunity that
a move to Oxford presented and was appointed Professor of
Clinical Neurology in 1987’ (Sir David Weatherall).
JND had a major impact on both medicine and the broader
aspects of university life during his time as the Action Research
Professor of Neurology in Oxford (1987–98). While managing an
increasingly active research group, and despite innumerable calls
on his time from activities outside Oxford, he maintained and
expanded the excellent clinical neurology services at the
Radcliffe Inﬁrmary. He recruited neurologist Michael Donaghy
and neurophysiologist Kerry Mills to Oxford as Clinical Readers,
and brought Margaret Esiri and the academic work of the neuro-
pathology department into neurology. He also appointed Peter
Rothwell as clinical lecturer; subsequently Rothwell created the
Stroke Prevention Unit, ﬁlling a gap left open by the departure
of Charles Warlow to Edinburgh. Remarkably, in the mid-1990s,
with Alan Cowey and George Radda, JND persuaded the MRC to
create a functional imaging centre. They brought back Paul
Matthews from London, Ontario, to direct it, and the Functional
Magnetic Resonance Imaging of the Brain (FMRIB) centre (now
directed by Professor Irene Tracey), has subsequently become a
world player in clinical and basic imaging and its applications.
‘Overall, in the 11 years that he held the Chair of Clinical
Neurology, he developed a remarkably active clinical department
with a research base stretching from the bedside to imaging and
immunology, and numbering over 60 scientists’ (Sir David
Weatherall).
‘John was also remarkably unselﬁsh about giving time to help
major organizational developments and activities in the medical
faculty. He was a very effective member of the Board of the
Faculty of Clinical Medicine from 1990–93 and chaired the
Animal Care Committee at the same time. This was a period
of rapid expansion of the medical faculty and John was a major
inﬂuence in many directions, always giving a solid and balanced
view of where the faculty should be going. He also served the
University as a delegate of the University Press for 5 years, a
rather terrifying body, which meets regularly each term and has
the last word on which books should be published by the Press.
His breadth of interests and balanced approach were of particu-
lar value to this heterogeneous group of academics. During this
time John also had many commitments outside Oxford including
time-demanding work for the Department of Health, the Royal
Society (elected Fellow of the Royal Society in 1991, Fig. 4A),
the Royal College of Physicians, and the British Association for
the Advancement of Science’ (Sir David Weatherall).
It was at a meeting of the British Association for the
Advancement of Science in 1983 that he attracted considerable
interest when he proposed that Samson had both myasthenia
gravis and autoimmune alopecia (Delilah gets off the hook) and
it was only following a spontaneous improvement in both diseases
that Samson’s hair grew and he was able to pull down the temple.
The media attention that followed this retrospective diagnosis did
not meet with everyone’s approval.
Medical Research Council
The 1990s were a time of change and challenges in research
funding. The former CEO of the MRC Sir Dai Rees writes
Figure 4 (A) At the Royal Society following election to Fellowship of the Royal Society, and (B) the Neurosciences Group in the courtyard
of the Institute of Molecular Medicine in 1991.
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much to help MRC through difﬁcult times. We had to learn
how to think in new ways about ﬁnances, about accountability
not only for the science but for political correctness’. The depart-
ures from MRC tradition threatened to dissolve the community
into warring tribes—basic versus clinical, direct support versus in-
direct, each discipline against others, primary care and public
health versus advanced diagnostics and treatment. The neurosci-
ence community had seen great glory in the past, and would see
more in the future, but the new challenge of sharing the glamour
and thus the resources with brightly plumaged new cuckoos such
as molecular biology and genetics, made some suspicious of the
MRC’s commitment. The proposed reforms of the Clinical
Research Centre, then at Northwick Park, struggled under the
baleful eye of the Prime Minister (Margaret Thatcher), particularly
when she became persuaded that the reforms represented a threat
to hospital access for her Finchley constituents. As Council
Member, and particularly as Chair of the Neurosciences Board,
John was in the eye of several storms. I had the impression that
he found it rather fun, respecting and even admiring the enthusi-
asm and honest commitments of the impassioned. With his emi-
nence and senior membership of key communities, and his cool
head but personal warmth, John could put the case for the greater
good with an authority and persuasiveness that outsiders to these
groups could not. The MRC could hardly be in such good shape
now without the dedicated and imaginative efforts of John and
the allies he gathered around him’ (Sir Dai Rees).
Editor of Brain and President of
the Association of British
Neurologists
As he began to plan for his ‘retirement’, John agreed to take
over from Ian McDonald as editor of Brain, a journal that John
had already served as secretary and treasurer (1977–81) and
as chairman of the Guarantors and Board of Management
(1994–99). Brain had acquired a reputation for being fusty,
and as the ‘Queen Square house journal’, but John had a
knack for snifﬁng out work that was forward looking and
contemporary; and he introduced electronic processing and
on-line publication well ahead of other journals in the ﬁeld
(Compston; Supplementary material F).
Another change was to appoint a Deputy Editor to help, and
John Rothwell (Institute of Neurology) proved to be an excellent
choice.
‘When John took over Brain, like all new editors, he wanted to
bring the journal up to date and for it to lose the rather ‘clubby’
aura that had become, rightly or wrongly, associated with it.
This didn’t imply a great change in editorial policy from Ian
McDonald, nor great changes in the ofﬁce, but he wanted to
make the journal one of the ﬁrst to enter the internet age. He
thought that this would broaden submissions, especially from
outside the UK, and appeal to a younger audience. He was
not in favour of editorial musings or long book reviews, which
at the time had tended to be dominated by a relatively small
circle of neurologists, but more emphasis on the new ﬁelds of
genetics and molecular biology. So we began the process of
transferring from a paper-based to an electronic journal. This
was in the days when most internet connections outside the
university were via telephone lines, so that keeping up with
submissions when on holiday or even at meetings, could be a
tedious business involving dropped connections and long pauses
in transmission of papers. It was also not without its teething
problems, since Brain was one of the ﬁrst large journals to be
taken on by the Manuscript Central system; but for a time this
was an advantage as we had a reasonable inﬂuence on how
they began to develop the site.
The transition was remarkably smooth, authors and reviewers
liked it and submissions began to increase dramatically. Impact
factors were beginning to enter the world of scholarly evalu-
ation and as more and more papers came in, the impact factor
gradually began to rise. As editors we felt that it was necessary
to try to limit the numbers of submissions for review. We
stopped considering papers that did not contain clinical data,
and often sent back papers if their main aim was to de-
scribe normal brain function. This meant a reduction in the
number of imaging papers, and more space for genetics and
molecular biology. Many thought this was an unfair policy
and perhaps it was, but it had the simplicity of being highly
transparent and easily understood. By the end of John’s
7-year stint, we were receiving 800–900 manuscripts each
year, and the acceptance rate was  20%. It had become an
unreasonable number for two editors to process, and was ripe
for change when the new editor, Alastair Compston took over‘
(Professor John Rothwell).
JND himself recalled later (ANA; Supplementary material C):
‘I wanted to try to change how the journal was perceived and
what it did. John Rothwell looked after the manuscripts in
neurophysiology, and we had superb support from Carol
Lovelidge and Lubna Zafar. I never took a holiday from the
journal for 7 years. There were no fast internet connections
and in the West Indies, or wherever, my latest little grandchild
vomiting down my back, being bitten by mosquitoes, perched
on the edge of a bath, I was still connecting – somewhat un-
certainly – with the online system via dial-up’.
Another activity was the Association of British Neurologists.
‘John also took an ofﬁce in Boswell Street as President of
the Association of British Neurologists. As a former secretary
(1981–84), medallist (1999), and the author of many papers
presented over several decades, it was natural that the mem-
bership wanted John to serve as President (1999–2000).
He felt that the Association had drifted away from its origins
in 1932 as a forum for discussing the best of British scientiﬁc
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scientists, he established a Clinical Research Advisory Committee
to foster the clinical sciences’ (Compston; Supplementary
material F).
Marriage and family life
JND’s ﬁrst introduction to Rosemary Schmid in 1960 was not
propitious. ‘I thought him much too quiet whereas he remem-
bered someone overconﬁdent who talked far too much’
(R. Newsom-Davis, personal recollection). However, they met
again at an opera party in 1963 and, with earlier prejudices for-
gotten, they married later that year. They settled in North London
and the arrival of children followed: Amelia (1970), Imogen (1972)
and Tom (1973). Rosemary worked as an educational psychologist
and early family life was split between London and their weekend
cottage in West Dorset. The family moved to Oxford in 1987, but
following his ofﬁcial retirement in 1998, he and Rosemary re-
turned to London, where the children were living and able to
visit regularly. Amelia now lives in Paris and works in media mar-
keting, Imogen is a paediatric neuropsychologist, while Tom fol-
lowed his father into medicine and is an oncologist. Rosemary
continues to live in West London.
‘Science and medicine were never far from JND’s mind.
Famously he even brought a choice selection of papers with
him on his honeymoon. However, when needed, he would
distract himself from work through cooking (an interest he in-
herited from his mother), gardening and his seven grandchil-
dren. He had a lifelong love of music, although he played
no instrument himself, and regularly attended concerts and
opera. Yet he was a reluctant tourist and on family holidays
would usually be seen contemplating his most recent manu-
script instead of admiring the relevant sights’ (Dr Tom
Newsom-Davis).
Research
In the account that follows, citations of JND’s work are
numbered and the full references can be found in
Publications (Supplementary material B). Only citations to others’
publications are detailed in the text and listed in the ‘References’
section.
Respiratory physiology
(1965–75) and myasthenia at the
National Hospital
Tom Sears, JND’s MD supervisor, friend and colleague, describes
their work together.
‘Moran Campbell had carried out experiments testing the ability
of human subjects to perceive increased resistive or elastic load-
ing of the airways; and he had drawn on contemporary ideas of
the ‘length follow-up servo control of movement’ to propose
imaginatively that perception depended on ‘length–tension’ in-
appropriateness to account for the results. However, the servo
theory at the time conceived a muscle spindle-dependent reﬂex
mechanism automatically subserving motor control without con-
scious intervention. In fact the conscious response to loading of
limb muscles at that time was assigned to joint receptors with
afferent pathways to the brain in the posterior columns. The
neurologist Richard Godwin-Austen had recently ﬁnished a
study of intercostal joint mechanoreceptors in the cat, examin-
ing these receptors as a possible source of chest wall proprio-
ception to account for dyspnoeic sensibility. Around that time I
was examining electromyographically the response of the inter-
costal muscles to altered mechanical loading (Sears, 1964). I
therefore suggested to John that he should investigate the per-
ception of load in patients with impaired position sense or other
criteria of posterior column dysfunction. On alternate weeks
John and I would impale each other with wire EMG electrodes,
inserted in the external or internal intercostal muscles (some-
times with uncomfortable consequences, ANA; Supplementary
material C), to examine their reﬂex responses to sudden
changes in pressure, which could either assist or oppose the
voluntary sustained lung volume, or a steadily decreasing or
increasing one; similarly, a solenoid valve was used to increase
or decrease the mechanical load (airway resistance). The re-
search was based on insights gained from intracellular record-
ings of the central respiratory drive and the monosynaptic
reﬂexes of intercostal motoneurons. In this way we were able
to provide a comprehensive account of the segmental reﬂex
responses of these muscles, particularly in relation to the topo-
graphical distribution of activities across the chest wall, as well
as to the lung volume (% vital capacity) at which the perturb-
ation was introduced (Supplementary materials B1 and B4).
Thus our conceptual framework centred on the muscle spindle
and John, who had access to human intercostal muscle biopsies,
subsequently used the same experimental rig to examine the
muscle spindles in these muscles, and provided the ﬁrst account
of their activation in his in vitro preparation (Tom Sears;
Supplementary material B8).
From this experience John gained invaluable experience in
electrophysiological measurements and subsequently became
very interested in hiccup (Supplementary material B3), and
described a new method to measure conduction velocity
of human phrenic nerve ﬁbres, which hitherto had de-
pended on oesophageal electrodes (Supplementary material
B2). Surface electrodes placed over the insertion of the dia-
phragm in the lower ribs provided clean EMG signals in re-
sponse to stimulation of the phrenic nerve in the neck, thus
providing objective data where the assessment of paradoxical
movement was equivocal.
In New York with Fred Plum from 1969–70, he carried out
experiments on the anaesthetized cat to determine the trajec-
tory of descending bulbospinal pathways responsible – ﬁrstly,
for the ‘central respiratory drive’ to respiratory motoneurons in
the spinal cord, and secondly, for those responsible for the
cough reﬂex (Supplementary material B5). Both questions had
their origin in work done at Queen Square, namely that of Peter
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cervical tractotomy for the relief of intractable pain; and our
studies on the effects of selective lesioning and stimulation ex-
periments in the medulla studied. The experiments were meticu-
lous and with excellent histological control to allow clear
conclusions concerning the innervations of the diaphragm and
abdominal muscles. Those responsible for the cough lay in the
ventral quadrant of the cervical spinal cord, whereas those car-
rying the respiratory drive were in a ventrolateral location, just
as Nathan had found for man (Supplementary material B5).
These feline studies epitomized John’s interest in seeking experi-
mentally to discover mechanistic explanations to illuminate his
clinical work.
John’s links with the emerging Department of
Neurophysiology continued while he was Physician-in-Charge
of the Batten Unit. He collaborated with the lecturer in
Bioengineering in that department, David Stagg, who developed
a comprehensive computer-based analysis of airﬂow and tidal
volume in eupnoea to reveal a complex breath-by breath vari-
ation in such individual parameters as inspiratory and expiratory
durations, cycle time, and their correlation with tidal volume
(Supplementary material B9). Nevertheless, this seemingly
random variability was such that mean inspiratory ﬂow rate
was held constant, the work providing a fresh insight concern-
ing the homeostatic regulation of breathing. Mike Goldman,
an expert on the use of ‘magnetometers’ for measuring
body wall displacements, then at the Harvard School of Public
Health, was encouraged to come to Queen Square. This led to a
further collaboration in which John, David Stagg and Mike
Goldman were able to show that magnetometers placed
over the ribcage and abdomen to measure changes in their
anterior/posterior diameters provided signals that, coupled to
a calibration procedure, allowed the assessment of respiratory
function without the need for face masks, a valuable method
for sick patients’ (Tom Sears; Supplementary materials B10
and B14).
JND did not entirely neglect this promising early work. Over
the next 10 years or so, many clinical studies on patients
with compromised ventilation were undertaken, many with anaes-
thetist Laurie Loh, who subsequently moved with JND to
Oxford (Supplementary materials B10, B11, B13, B14, B15, B24
and B25).
Myasthenia
It was the intercostal muscle preparation that, in 1973, while
Physician-in-Charge of the Batten (Intensive Care) Unit, changed
the direction of JND’s career. As mentioned above, Tom Sears had
been contacted by Ricardo Miledi, an electrophysiologist of
great distinction who had spent most of the preceding 20 years
with the 1969 Nobel Laureate (later Sir) Bernard Katz, in
the Biophysics Department at University College London.
Together they described many aspects of the physiology of neuro-
muscular transmission in species from squid to man,
including seminal work on the role of calcium in acetylcholine
release, and had just published the ﬁrst observations on the
electrical ‘noise’ that resulted from application of acetylcholine,
and which provided data that could be used to calculate the be-
haviour of single acetylcholine receptor (AChR) ion channels (Katz
and Miledi, 1970).
Miledi was medically trained and had followed the work of
Elmqvist and colleagues (1964) showing reduced amplitude of
the miniature endplate potentials in muscles from patients with
myasthenia gravis, a disease that had been thought to affect
neuromuscular transmission since Jolly’s ﬁrst electromyographic
description (Jolly, 1895). Those observations did not fully resolve
the question as to whether the defect was presynaptic—due to
reduced release of acetylcholine—or postsynaptic, potentially due
to defects in the AChR itself. Miledi had recently used the snake
toxin  -bungarotoxin, originally discovered by Chang and Lee
(1963) in Taiwan, to quantify and purify AChRs from ‘Torpedo’
electric organs and from rat muscle (Miledi et al., 1971).
It seemed likely that bungarotoxin could be used to analyse
AChRs at myasthenia gravis endplates—but he needed to ﬁnd
someone who could provide human muscle biopsies. JND, as
part of his work in the Batten Unit, frequently had patients with
myasthenia gravis under his care and, with an introduction from
Tom Sears, a highly successful collaboration was quickly estab-
lished. Intercostal muscle samples were obtained at thymectomy
with minimal risk to the patients. Control muscle samples were
available from the London Chest Hospital, mainly from patients
undergoing thoracotomies, through the help of chest surgeon Mr
Marvin Sturridge who also did the thymectomies at Queen
Square.
Within a few weeks, the ﬁrst muscle biopsies began to arrive
at UCL; endplate recordings were made by visiting postdoc
Yushi Ito who conﬁrmed that  -bungarotoxin inhibited human
muscle neuromuscular transmission and that the miniature end-
plate potentials were indeed substantially reduced in amplitude
at myasthenia gravis endplates. The remaining muscle was
immersed in radioactive
125I- -bungarotoxin and the muscle
ﬁbre bundles dissected into small sections containing the end-
plates. Counting these for radioactivity showed that the number
of
125I- -bungarotoxin-binding sites, and thus the AChRs, were
substantially reduced, which was conﬁrmed by autoradiography.
Unfortunately, Fambrough et al. published their very similar results
in Science in 1973. Having been thoroughly scooped, JND
and Ricardo concentrated on making their study more comprehen-
sive, and it was published in Brain in 1978 (Supplementary mater-
ial B18).
Meanwhile, another visiting postdoc Peter Molenaar, had
shown that acetylcholine was increased in myasthenia gravis
muscle, and in rats treated with bungarotoxin or immunized
against AChRs (Supplementary material B26). These observations
implied that, in the presence of reduced AChR function, there
might be compensatory increases in acetylcholine synthesis and
release—ﬁndings that were later conﬁrmed when Molenaar, visit-
ing the Royal Free Hospital, showed an increase in choline acetyl
transferase, the enzyme responsible for acetylcholine synthesis
(Supplementary material B34), and subsequently investigated in
more detail in both myasthenia gravis and AChR-immunized rats
(Plomp et al., 1994).
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myasthenia gravis
During the mid-1970s JND continued to work on intercostal
muscle spindles, including describing the endplate morphology in
myotonic dystrophy with his postdoc David Strannock
(Supplementary materials B21 and B22). The move to concentrate
on myasthenia gravis followed the exciting developments in the
USA where antibodies to AChRs were ﬁrst identiﬁed both in ani-
mals immunized against puriﬁed receptors (Patrick and Lindstrom,
1973) and in patients with myasthenia (Lindstrom et al., 1976),
and the demonstration that injection of IgG puriﬁed from patients
with myasthenia gravis reduced miniature endplate potentials and
AChR numbers, and caused evident weakness, in mice (Toyka
et al., 1975). Extrapolating from the use of plasma exchange in
patients with Goodpasture’s syndrome, Tony Pinching and Keith
Peters tried the treatment on two patients with acquired myasthe-
nia gravis and one with congenital myasthenia (Pinching and
Peters, 1976); their observations were extended by Pinching,
(Newsom-)Davis and Peters in 1977 (Supplementary material
B17). The rapid (within 1–2 days) and impressive temporary im-
provement obtained by simply removing a large proportion of
circulating plasma proteins was probably what convinced JND
to move from respiratory neurophysiology and concentrate on
myasthenia gravis. He obtained a project grant from the MRC,
recruited A.V. who had been doing some of the myasthe-
nia gravis work in Miledi’s laboratory, and set up the re-
search group at the Royal Free Hospital with much support
and enthusiasm from P. K. Thomas (Vincent; Supplementary
material G).
During this time JND showed his adaptability by taking Ivan
Roitt’s “post-experience immunology” evening course so that he
was soon fully au fait with this ﬁeld.
Myasthenia at the Royal Free Hospital
JND’s approach to the research that began at the Royal Free
Hospital and subsequently transferred to Oxford, was that few
projects were completed and then dropped—almost every disease
area was pursued and extended, or taken up again when more
suitable techniques became available. His achievements (Table 1),
which were based on building up a stable multidisciplinary team,
involved all of the diseases of the neuromuscular junction and the
history of his work on each of these conditions stretches over
some time (Fig. 5). In the passages that follow, most of which
represent many overlapping years of endeavour, the scientists and
clinical fellows who performed the work will be named. This is not
to diminish JND’s contributions—in fact, he was always deeply
involved with everything going on—but to show that he chose
able scientists and clinicians, encouraged visitors from around the
world, and inspired enthusiasm and commitment, while allowing
the growing team a good deal of independence. As a result, the
team survived after his retirement and several aspects of the work
have continued, as will be brieﬂy recounted below.
The questions that ﬁrst needed to be answered were obvious.
How much did the antibodies fall after plasma exchange, and did
their levels correlate with clinical indices of disease? The results in
seven patients, including one with congenital myasthenia who had
no detectable AChR antibodies and did not improve clinically,
otherwise showed a remarkable inverse correlation—not only
as the AChR antibodies fell following the exchanges, but also as
they subsequently rose (Supplementary material B19). At this time
the main additional immunosuppressant was azathioprine, follow-
ing the pioneering work by Mertens et al. (1969). AChR antibody
levels fell only slowly after azathioprine [although signiﬁcantly
faster in patients with thymoma than those without
(Supplementary material B28)], perhaps explaining why there
appeared to be no extra beneﬁt or synergy of plasma exchange
combined with immunosuppression (Supplementary material B28).
It was many years before JND and Jackie Palace performed the
seminal trial of prednisolone alone versus prednisolone plus
azathioprine (Supplementary material B212) demonstrating that
azathioprine reduced the maintenance dose of prednisolone
required to achieve clinical remission, but that this effect took
10 months to be evident. Not only has the combination of
azathioprine and prednisolone become the main ﬁrst line immuno-
suppression in myasthenia gravis: the trial approach has been
adopted for other studies in myasthenia gravis.
The thymus and antibody synthesis
One of the ﬁrst projects JND became enthusiastic about at the
Royal Free Hospital was the study of the thymus for which he
joined forces with Glenis Scadding, a clinical fellow working with
Howard Thomas, at that time a clinical lecturer in Dame Sheila
Sherlock’s renowned Hepatology Department. Scadding was cul-
turing thymic tissue explants in order to test for AChR antibody
production. Indeed, the antibodies were present in the culture
Table 1 Deﬁning the clinical spectrum, molecular mechanisms and treatment responses in neuromuscular junction
disorders
Establishing the importance of plasma exchange for treatment and for identiﬁcation of antibody-mediated mechanisms.
Exploring autoantibody-mediated pathogeneses by experimental in vitro and in vivo studies.
Identifying target molecules and devising more speciﬁc diagnostic antibody assays.
Describing immunogenetics, and the immunopathology of the thymus and antigen-speciﬁc T-cell responses.
Establishing the genetic basis and molecular targets in inherited forms of myasthenia.
Developing systematic ﬂow charts for diagnosis and treatment.
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assay conditions. A preliminary report appeared while Scadding
was on maternity leave (Supplementary material B23), but she
subsequently wrote a full report after longer gestation
(Supplementary material B38). The production of antibodies by
the thymus—only seen in those patients with a ‘hyperplastic’ thy-
mus—was an exciting, although at ﬁrst controversial, ﬁnding.
When presented with the early data, leading immunologist Av
Mitchison walked out of the room muttering something about
‘the thymus doesn’t contain B cells and doesn’t produce antibo-
dies’! Nevertheless, it prompted recruitment of a real immunolo-
gist, Nick Willcox, allowing many future studies on the thymus,
the T, B and plasma cells (see below), but also on the effects of
thymectomy on antibody levels. Despite several publications from
other groups claiming no convincing effect, careful analysis
showed a clear inﬂuence of thymectomy alone on AChR antibody
levels, which declined on average by  50% over a year in patients
with hyperplastic thymi (Supplementary material B53), but not in
thymoma patients, as predicted from their poorer clinical response.
Human leukocyte antigen and disease
diversity
One of his most cited myasthenia gravis papers resulted from
JND’s collaboration with a trainee at Queen Square, Alastair
Compston, and his PhD supervisor Richard Batchelor. Batchelor
had been involved with the early blood grouping and tissue
typing studies at East Grinstead, and recognized their value in
demonstrating genetic associations with autoimmune diseases.
Compston was working principally on multiple sclerosis but enthu-
siastically undertook to analyse 68 blood samples from patients
with myasthenia looking, as one had to in those days, for evidence
of human leukocyte antigen (HLA) type by serological
cross-matching of fractionated T and B lymphocytes. The results
conﬁrmed the high incidence of the HLA B8-DR3 haplotype in
myasthenia; but it was restricted to younger patients, whereas
HLA B7-DR2 was more frequent if onset was after the age of
40 years (Supplementary material B30). Thymoma cases, con-
sidered separately for the ﬁrst time, did not show a speciﬁc HLA
association. This study has not only stood the test of time but
clearly indicates the importance of age and pathology stratiﬁcation
of patients when analysing their genetic associations—even when
the ﬁnal disease mechanisms, AChR antibodies in this case, are the
same.
JND’s work became an attraction for visiting fellows and several
contributed over the next few years. Ho-Chang Chiu came from
Taiwan with sera from his patients with myasthenia gravis who
were younger than the Caucasians, a high proportion presenting
at 510 years of age. These were both males and females and
mostly had ocular or mild myasthenia, with relatively low AChR
antibodies (Supplementary material B83). There were also
immunoglobulin allotype differences in Japanese patients, who
showed an association, that Taiwanese or Caucasians did not
(Supplementary material B95). Clinical fellow, Stephanie Robb,
found another difference from asymptomatic Japanese subjects
who reportedly showed raised levels of antibodies to AChR,
which she did not ﬁnd in a small study of elderly individuals
from the UK (Supplementary material B71). Both of these studies
have been followed up more recently with analyses of myasthenia
Figure 5 Timeline. MG = myasthenia gravis.
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and of AChR antibodies in older people with and without diag-
nosed myasthenia gravis (Vincent et al., 2004).
Antibody characterization
The ﬁrst full study of AChR antibodies in samples sent for routine
serological assays (n = 2967) was not published until 1985, when
it compared the levels of antibodies with those found in 153
validated cases from JND’s clinic (Supplementary material B73).
Meanwhile, detailed characterization of the antibodies and the
antigenicity of the AChRs were described in patients with general-
ized, ocular or penicillamine-induced myasthenia, with recent
onset of disease, or with very low AChR antibodies. This work
highlighted the great heterogeneity of the antibodies in afﬁnity,
subclass, light chain isotype, cross-species reactivity, competition
with monoclonal antibodies (see below) and reactivity with differ-
ent epitopes on AChR from normal, denervated and ocular
muscles. It also indirectly demonstrated an antigenic difference
between normal and denervated (foetal) AChRs and even
between the two bungarotoxin-/acetylcholine-binding sites
(Supplementary materials B45, B46, B54 and B74).
By 1979, JND had recruited a new postdoc, Bethan Lang (from
Eric Barnard’s laboratory at Imperial College London), to purify the
patients’ antibodies by afﬁnity chromatography (Supplementary
material B41). Beth proceeded to study anti-idiotype anti-
bodies—which bind speciﬁcally to the antigen-combining site or
other unique epitopes on the AChR antibodies themselves—by
immunizing rabbits with the puriﬁed antibodies. However, the re-
sulting ‘anti-idiotypic’ antibodies did not cross-react with AChR
antibodies from other patients except in one case
(Supplementary material B66), indicating that most patients’ anti-
bodies were idiotypically distinct.
The next recruit was Paul Whiting, JND’s ﬁrst MRC PhD stu-
dent; this was very fortunate as Paul was an exceptionally modest
but effective young man who later worked with Jon Lindstrom at
the Salk Institute, returned to Pharma in the UK and is now
Executive Director and Site Lead of Pﬁzer’s Regenerative
Medicine Research Unit. Whiting puriﬁed human AChRs from
amputated limbs—a gruesome business that often meant travel-
ling around London on the underground or buses carrying large
smelly bundles wrapped in black plastic bags. He produced mono-
clonal antibodies against the human AChR that he then used to
characterize the AChRs and their antibody-binding sites by com-
petition assays. Not unexpectedly, Whiting’s monoclonal antibo-
dies proved to be highly speciﬁc for different regions on human
AChR isoforms, rather more discriminating than most raised
against ‘Torpedo’ electric organ by Socrates Tzartos working
with Jon Lindstrom and colleagues (1981). In particular, four
monoclonal antibodies bound only to AChRs from denervated
(extrajunctional/foetal type) muscle and not from the adult neuro-
muscular junctions (Supplementary material B82). This conﬁrmed
the molecular distinction, demonstrated by the cloning of the
genes in 1985 (Shibahara et al., 1985). These monoclonal anti-
bodies also allowed A.V. to convince herself of the absence of
anti-idiotypic antibodies in myasthenia gravis, challenging the
prevailing hype (Vincent, 1981). Later a PhD student, Andy
Roberts (now at Cambridge Antibody Technology), induced
anti-idiotype antibodies against some of the monoclonal antibo-
dies, but they did not cross-react with human AChR antibodies
(Supplementary material B147).
Whiting, and subsequently visiting clinical fellow, Fedor
Heidenreich, used these monoclonal antibodies in further compe-
tition experiments to characterize the antibodies in thymoma,
early- and late-onset groups and in serial samples during treat-
ment (Supplementary materials B75, B81 and B98). Heidenreich
went on to show close similarities in speciﬁcities between the pa-
tient’s antibodies in thymic culture supernatants and serum pre-
and post-thymectomy (Supplementary material B100), indicating
that the thymus was indeed a likely source of the full repertoire of
antibodies. Some years later, clinical training fellow Jeremy Farrar
(now Director of the Oxford University Clinical Research Unit in
Ho Chi Mingh City, Vietnam), supervised by Nick Willcox, was
able to recombine the heavy and light chain genes from messen-
ger RNA expressed in the thymus of a patient with myasthenia
gravis and demonstrate the diverse germ-line gene origins of the
antibodies (Supplementary material B191).
Disease mechanisms
Much had been learnt about disease mechanisms in the 1970s
from the laboratories of Andrew Engel, Jon Lindstrom, Dan
Drachman, Zach Hall and many others. These had shown that
the antibodies could inhibit acetylcholine or  -bungarotoxin bind-
ing to rodent receptors (Weinberg and Hall, 1979), and reduce
the surface expression of AChRs on cultured cell lines by a pro-
cess known as antigenic modulation—cross-linking and internaliza-
tion of the receptors followed by their degradation (Stanley
and Drachman, 1978). And perhaps most importantly, by
complement-dependent damage to the receptor-containing
postsynaptic membrane following antibody binding (reviewed
by Engel et al., 1984). These three mechanisms are still thought
to be the most important in AChR antibody-positive myasthenia
gravis. Steve Wilson, JND’s ﬁrst clinical fellow, asked whether anti-
genic modulation really operated at the neuromuscular junction
where the natural turnover of AChRs is very slow (half-life 10
days). By injecting radioactive  -bungarotoxin into pleural cavities
of mice that had been injected systemically with myasthenia gravis
antibodies, he was able to label the diaphragm AChRs and show
that they did indeed turnover faster (see also Stanley and
Drachman 1978), but, unexpectedly, their synthesis rate also
increased. These were highly relevant ﬁndings at the time, but
having been turned down by Nature and with Wilson returning
to neurology as a Senior Registrar, they were published a little less
prestigiously (Supplementary materials B56 and B57).
There are still, however, several unexplained effects of myasthe-
nia gravis serum on neuromuscular junction functions. Andy
Lerrick, a visiting medical student from the USA, joined Dennis
Wray, a lecturer at the Royal Free Hospital (now recently retired
as Professor of Biophysics at Leeds University), an experienced
electrophysiologist who began a very fruitful collaboration with
JND (Ricardo had left London for the University of California at
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inhibitory effect of myasthenic serum on miniature endplate po-
tential amplitudes was found; this was heat-sensitive, not appar-
ently in the IgG fraction, and its nature has never been adequately
explained (Supplementary material B49).
Cloning the acetylcholine receptor
genes and different human acetylcho-
line receptor isoforms
By 1986, genetic forms of myasthenia were beginning to be stu-
died and it was clear to JND that this would be a fruitful area for
the future. He recruited David Beeson who, like Bethan Lang, had
done his PhD with Eric Barnard at Imperial College, expressly to
clone and sequence AChR genes, supported by a grant from the
Muscular Dystrophy Group (now Campaign) to JND and Barnard.
The ﬁrst Torpedo and Electric eel AChR subunits had been cloned
in Barnard’s laboratory, in Japan and in the USA, and Beeson had
already managed to describe chicken AChR gene sequences and
expression during his PhD, but JND wanted the human sequences.
It is hard to appreciate how difﬁcult this was in those days, with
no kits, and techniques that had to be composed more or less
from scratch. But not only did JND want to be able to study
patients with congenital myasthenic syndromes but AChR poly-
peptides were needed for Willcox’s T-cell studies (see below).
The ﬁrst human subunit to emerge from Beeson’s work was the
b (Supplementary material B109), and then he and postdoc Alison
Morris discovered a novel exon of the human   subunit, which
was generated by alternative splicing and did not appear to be
present in other species, apart from close primates. This encoded
an extra 25 amino acids and the two isoforms could be distin-
guished by means of antibodies to the additional 25 amino acids,
raised in rabbits by research assistant Leslie Jacobson
(Supplementary material B132). The two isoforms appeared to
be equally expressed in different human muscles (Supplementary
material B151) and also in the thymus. However, regrettably the
expression of the isoform with the additional 25 amino acids did
not result in a functional AChR when the complementary DNAs
were injected into Xenopus oocytes by postdoc Claire Newland
(Supplementary material B178), and to date, no role for this
quirk of human genetics has been found either in neuromuscular
junction function or in myasthenia.
Meanwhile, Beeson had also produced the ﬁrst primary comple-
mentary DNA sequences for the   and " subunits of the human
AChR, which by that time were realised to deﬁne the foetal and
adult AChRs, respectively (Supplementary material B149), and he
had also identiﬁed the chromosomal localization for the human  ,
b,   and " subunits (Supplementary material B120). This, and the
growing expertise in RNA as well as DNA technologies, enabled
clinical training fellow Cal MacLennan to study the expression of
the foetal and adult-deﬁning subunits in human extraocular mus-
cles (Supplementary material B194), conﬁrming the earlier obser-
vations suggesting that these muscles did not contain large
amounts of foetal AChRs despite their multiply-innervated
muscle ﬁbres (Supplementary material B46), and questioning the
hypothesis put forward by Henry Kaminski and Robert Ruff (1997)
that ocular myasthenia gravis was due to antibodies speciﬁcally
directed at the foetal AChRs. Indeed, the extraocular muscles
turned out to express a high concentration of RNA for the
adult-speciﬁc " subunit, and this suggested that adult AChR
might be an important target for antibodies in patients with
purely ocular myasthenia gravis, as was shown by comparing
their serum reactivity with AChRs extracted from muscle cell
lines that had been engineered to produce large amounts of
either foetal or adult isoform (Supplementary material B194).
Use of the two isoforms, and their expression in Xenopus
oocytes, enabled the group to investigate a rare but devastating
condition. A few mothers with myasthenia gravis had been re-
ported to have babies born with arthrogryposis multiplex con-
genita—multiple joint contractures, often with other deformities
and resulting from lack of foetal movement. JND, David Hilton-
Jones, a consultant neurologist in Oxford, with Jane Hurst and
other clinical geneticists, had diagnosed myasthenia gravis in a
mother with four consecutive affected babies, three of whom
had died perinatally (Supplementary material B170); moreover,
another female without any history of myasthenia gravis had
ﬁve affected pregnancies (Supplementary material B181). This
suggested that AChR antibodies in these unfortunate females
were crossing the placenta and paralysing the foetus during de-
velopment; their ability to inhibit the function of foetal AChRs,
while leaving the adult form unaffected (although still a target
for some less inhibitory antibodies), was convincingly demon-
strated by Claire Newland, David Beeson and visiting medical stu-
dent Sietske Riemersma (Supplementary material B189). The role
of the antibodies in this condition was formally conﬁrmed by Leslie
Jacobson and visiting paediatric fellow Agata Polizzi, by injecting
pregnant mice with the antibodies and showing arthrogryposis and
perinatal death in the offspring (Jacobson et al., 1998). Some time
later, Ian Matthews, a postdoc supported by the Association
Francaise contre les Myopathies, made a recombinant library
from the thymus gland of the original mother; the cloned and
recombined antibodies were highly mutated and almost entirely
speciﬁc for foetal AChRs (Matthews et al., 2002).
Expanding the immunology—animal
models, thymus, germinal centres and
myoid cells
The thymus and antibody formation
The ﬁnding of antibody synthesis by the thymus was exciting.
Fortunately, JND was able to convince the scholarly and talented
(albeit somewhat eccentric) immunologist Nick Willcox, who like
JND had qualiﬁed at the Middlesex Hospital, to abandon a
tenured lectureship in anatomy in Newcastle in 1979 and join
the team at the Royal Free Hospital, supported by JND’s newly
awarded MRC programme grant. Willcox set about investigating
the cells that were involved in the thymus and also in the blood,
where a small amount of antibody synthesis could also be stimu-
lated with mitogens, as demonstrated in preliminary experiments
by neurologist Charles Clarke. Postdocs Gillian Harcourt and Andy
Jermy, together with research assistant Chris Fisher, began to ex-
plore antigen-speciﬁc T cells and animal models.
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terial B80). Lindstrom, Lennon, Patrick and their co-workers had
immunised mice actively with electric ﬁsh AChR emulsiﬁed in the
standard strong adjuvant. But Scadding found that she could
induce antibody levels against mouse AChR by injecting mouse
AChR-expressing membranes intrathymically or intraperitoneally
without adjuvant. These antibodies were at least partially patho-
genic, since miniature endplate potentials were modestly reduced
in amplitude in the mice studied by Dennis Wray and his student
Chris Prior (Supplementary material B80). These surprising ﬁndings
were explored in different strains of mice by Andy Jermy using
adoptive transfer approaches to prove that the antibodies were
T-cell-dependent (Supplementary material B111); BALB/c mice
injected with mouse AChR often became overtly weak with anti-
bodies very similar to those found in human myasthenia gravis
(Jermy et al., 1993).
Although the mice in these and other animal models showed no
abnormalities in the thymus, its involvement in the human disease
became a major focus of JND and Willcox’s work over the next
few years. This began at the Royal Free Hospital with crucial help
from Professor George Janossy and his Immunology Department
where immunohistological studies began to dissect the role of the
medullary germinal centres, so similar to those found in peripheral
lymphoid tissue. The germinal centres correlated with AChR titre
and thymic antibody synthesis, suggesting the presence of both
CD4 lymphocytes and antigen-presenting cells in the medulla; and
the accessibility to peripheral-type T cells appeared to create
opportunities for their autoimmunization (Supplementary materials
B44 and B63), though it was not clear what was initiating the
aberrant development of germinal centres. One early possibility
was viral infection of the thymus, but investigations by PhD
student, Linda Klavinskis, argued strongly against that
(Supplementary materials B64 and B65). It had been suggested,
however, that AChR was present in the rare medullary thymic
myoid cells, and this was conﬁrmed when visiting clinical fellow
Myriam Schluep used the AChR monoclonal antibodies to stain
the thymus (Supplementary material B90). Despite their rarity,
the myoid cells were often close to the germinal centres, implicat-
ing them in their formation (Supplementary material B202), and
thus in autoantibody diversiﬁcation. Indeed, postdoc Ian Matthews
with visiting clinical fellow Hiro Shiono, together with Glasgow
immunologists Gary Sims and David Stott, subsequently showed
that the IgGs cloned from the thymic B cells were highly mutated
(Supplementary material B278; Shiono et al., 2003a). An import-
ant observation, not widely appreciated, was that pre-treatment of
the patients with steroids altered the thymus and thymoma archi-
tecture and cell populations, particularly the cortical lymphocytes
(Supplementary material B118).
In the 1990s, several groups detected expression of isolated
AChR subunits in thymic epithelial cells from non-thymoma pa-
tients (Wakkach et al., 1996; Supplementary material B279). As a
result of a collaboration between David Beeson, Henri-Jean
Garchon (Paris) and Bruno Kyewski (Heidelberg), a predisposing
polymorphism of the AChR   subunit gene was found to inﬂuence
AChR expression in the epithelial cells, particularly under the in-
ﬂuence of a protein called the Autoimmune Regulator (AIRE; see
below; Giraud et al., 2006).
Thymoma
Collaborating with Mary Ritter (Royal Postgraduate Medical
School), JND and Willcox also scrutinized myasthenia
gravis-associated thymomas, noting combined expression of cor-
tical and medullary markers on the neoplastic epithelial cells and
excess generation of maturing T cells (Supplementary material
B92), many of which clinical training fellow Camilla Buckley
showed are exported to the periphery (Supplementary material
B233). They proposed the common ancestry of both normal and
neoplastic thymic epithelial subsets that is now generally accepted.
How the thymoma induces AChR antibodies was hotly debated
but, despite claims from others, neither expression of whole AChR
nor spontaneous synthesis of AChR antibodies was detected in
thymomas (Shiono, 2003a, b), although clinical training fellow
Cal MacLennan and David Beeson found high AChR "-subunit
expression (Supplementary material B279), and research assistant
Nita Nagvekar cloned AChR-speciﬁc T cells from two myasthenia
gravis thymomas (Supplementary material B209).
In later studies with Tony Meager at the National Institute of
Biological Standards and Control (Supplementary materials B225,
B249 and B255), however, it was found that antibodies were present
in thymoma patients that could neutralize interferon- ’s and inter-
leukin 12, and Camilla Buckley showed that these antibodies often
increased substantially in the circulation when thymomas recurred
(Supplementary material B234). The presence of these neutralizing
antibodies may well explain the susceptibility to infections frequently
found in association with recurrent thymomas. By a happy coinci-
dence, much later Meager and Willcox identiﬁed similar antibodies
in the monogenic autoimmune polyendocrine syndrome-I (APS-I,
alias APECED) (Meager et al., 2006; Kisand et al., 2010), which is
due to mutations in AIRE, that normally ensures that medullary
thymic epithelial cells express low levels of peripheral autoantigens
like insulin and AChR- , presumably to tolerize T cells.
Acetylcholine receptor-speciﬁc T cells
The production of AChR antibodies in the myasthenia gravis
thymus, and their correlation with thymic histology
(Supplementary material B38), suggested a primary role for locally
expressed AChR (Supplementary material B36). Nevertheless,
some AChR antibody production continued after thymectomy,
so there must also be peripheral synthesis. This was the major
focus of JND’s early work at the Royal Free Hospital where evi-
dence of control by speciﬁc T cells exported from the thymus was
pursued by investigating the cell types involved in both thymus
and blood (Supplementary materials B55 and B62), and in serial
studies of patients with myasthenia gravis (Supplementary material
B69). For this it was important to have puriﬁed AChRs initially
obtained from the electric organs of ‘Torpedo’. Visiting clinical
fellow Norbert Sommer found that AChR-reactive T cells were
present in both patients and controls (Supplementary material
B137), probably indicating incomplete deletion of autoreactive T
cells in the thymus. Moreover, both myasthenic thymi and thym-
omas appeared to be selectively enriched in AChR-reactive T cells
(Supplementary material B129).
With the cloning of the human AChR subunit genes by David
Beeson, and the growing use of synthetic peptides (ﬁrstly from
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neurologist Ben Ong, ﬁrst stimulated speciﬁc T cells from patient
thymus or blood with recombinant human AChR polypeptides,
carefully puriﬁed by Nadia Pantic, cloning the responding T cells,
and then mapping the epitopes with unusually long, and then
shorter overlapping peptides, made by Leslie Jacobson. One
AChR-speciﬁc T-cell clone from an HLA-DR3/4 heterozygous
early-onset myasthenia gravis patient’s thymus demonstrated a
role for a recurring
86Gly$Val dimorphism in the presenting
HLA Class II molecules (a collaboration with John Bell and Paul
Wordsworth in the Human Immunology Group at the Weatherall
Institute of Molecular Medicine; Supplementary material B134).
This was explored further by visiting neurologist Simon Hawke,
who found that the
86Gly allowed binding of anchor residues
with bulkier side-chains like the
149Trp of the AChR 147–160 epi-
tope; surprisingly this was recognized only when presented by
DR4, especially the DR4 subtypes that predispose to rheumatoid
arthritis (Hawke et al., 1999), and not by the common myasthenia
gravis-associated DR3. Possible relevance to myasthenia gravis,
however, was shown by visiting postdoc Fulvio Baggi who demon-
strated that the same clone responded to its epitope when pro-
cessed and presented from the endogenous AChR by an
HLA-DR4-transfected TE671 AChR-expressing cell line
(Supplementary material B148), while visiting neurologist Nils
Erik Gilhus showed that thymoma epithelial cells could also present
this and other peptide epitopes to speciﬁc T cells (Supplementary
material B173).
Despite these early successes, the team soon encountered a
major problem. The recombinant AChR subunits were made
from Escherichia coli; it was much easier to clone T cells against
the E. coli contaminants than against ‘real’ epitopes processed
naturally from whole AChR (Supplementary material B176).
Responses to shorter peptides were probably not the answer as
they were not naturally processed. The visiting overseas clinical
fellows (including Mike Nicolle, Hidenori Matsuo and
Anna-Paola Batocchi) carefully compared the speciﬁcities of the
T cell lines with clones they had raised in parallel against synthetic
AChR peptides, rather than recombinant subunits. The responses
to native AChR, captured by monoclonal antibodies onto immu-
nomagnetic beads, demonstrated which clones were truly AChR
speciﬁc (Supplementary material B144). In contrast, T cells se-
lected initially against synthetic peptides showed no detectable
responses to whole AChR (Supplementary material B176), prob-
ably because the T cells had been selected against peptides loaded
unnaturally into Class II molecules on the surface of the antigen-
presenting cells rather than via the endosomal pathway.
More encouragingly, clinical training fellow Marguerite Hill
starting with recombinant " subunit isolated clones responding
to an extracellular human AChR "201–219 epitope from three
of four patients with early-onset myasthenia gravis and one with
D-penicillamine-induced myasthenia gravis (Supplementary mater-
ials B217 and B218). Overall, the eight native AChR-speciﬁc
clones that were identiﬁed all recognized extracellular AChR epi-
topes and were presented to the different T-cell receptors often by
‘minor’ Class II molecules (HLA-DQ, -DP and -DR52a) rather than
the HLA-DR molecules that associate strongly with myasthenia
gravis. The results of these long years of toil strongly suggested
that speciﬁc T cells in patients with chronic autoimmune diseases
are rare, and questions the ease with which others have identiﬁed
‘speciﬁc’ responses to short peptides or intracellular proteins in
other diseases.
The identiﬁcation of a potentially dominant pathogenic epitope
raised the possibility of a ‘magic bullet’ approach for selective
therapy in myasthenia gravis. Visiting neurologist Mike Nicolle
(Supplementary material B166) found that cloned T cells could
be substantially inhibited by pre-treatment with speciﬁc soluble
peptide: HLA-DR4 complexes without co-stimulation (prepared
by collaborators at Anergen, a US Biotech company). Moreover,
they induced apoptosis in the T cells, and thus seemed promising
as long-term therapeutics. This was later taken up by postdocs
Alison Bond, Louise Corlett and John Curnow to deﬁne more pre-
cisely the underlying mechanisms and to explore alternative stra-
tegies (Supplementary material B203), e.g. using AChR" peptide:
Class II tetramers. Unfortunately, the MRC Programme grant
came to an end with JND’s retirement, and the project never
came to fruition.
One other aspect that was not taken forward was the study of
HLA Class I. The HLA associations in early-onset myasthenia gravis
span the HLA-DQ2-DR3-B8-A1 haplotype, but are consistently
stronger with the Class I molecule-B8 than with -DR3
(Supplementary material B220). John Curnow focused on
CD8-mediated immune responses towards human myoblasts,
hoping to explain auto-sensitization in vivo and the role of Class
I in disease susceptibility (Curnow et al., 1998, 2001).
Congenital myasthenic syndromes
One of the striking, but not altogether unexpected, observations
that JND made in the 1970s was that patients with myasthenic
symptoms from early childhood did not respond to plasma ex-
change [and did not have AChR antibodies (Supplementary ma-
terial B29)]. Meanwhile Andrew Engel in the Mayo Clinic had
began to study patients with inherited, presumed genetic, condi-
tions including the Slow Channel Syndrome, in which the duration
of miniature endplate potential and endplate potential amplitudes
are grossly abnormal, resulting from prolonged openings of the
individual AChR ion channels (Engel et al., 1982). This is often a
slowly progressive disease that may present in adulthood, as
described in two cases by JND with Hans Oosterhuis in
Groningen (Supplementary material B89). In general, patients
with congenital myasthenic syndromes (CMSs) can develop
arthrogryposis in utero, be ﬂoppy or intermittently weak from
birth, or develop weakness later on. Although often not progres-
sive, some forms are potentially life-threatening, particularly
during infancy (Engel et al., 2010).
A detailed study of ﬁve cases, started in collaboration with
Ricardo Miledi and two of his visiting fellows, Stuart Cull-Candy
and Alain Trautmann, found heterogeneity between the patients
in terms of their miniature endplate potential amplitudes and
AChR numbers (Supplementary material B39). Whereas four pa-
tients, including two brothers, had reduced AChRs, not dissimilar
to those in many patients with myasthenia gravis, one patient had
completely normal AChR numbers despite very small miniature
endplate potential amplitudes [later identiﬁed by postdoc Richard
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causing abnormally small AChR channel openings]. JND, often
with Peter Molenaar, continued to study muscle biopsies of pa-
tients with CMS, with Nick Murray at the National Hospital and
Dennis Wray at the Royal Free Hospital, and later in Oxford with
Kerry Mills at the Radcliffe Inﬁrmary and Mark Roberts or postdoc
Richard Webster doing the in vitro work. The neuromuscular junc-
tion defects were described in a large number of cases, in most of
whom the molecular defects were eventually identiﬁed many years
later.
In the 1990s, with the advent of the polymerase chain reaction
and advances in sequencing techniques it became feasible to
screen genes efﬁciently for mutations. As the genes encoding
human proteins were cloned and the primary sequences deter-
mined (Supplementary materials B109 and B149; Buckle et al.,
1996), research assistant Rebecca Croxen and clinical fellow Phil
Nicolls were able to identify mutations in AChR and rapsyn genes.
The work really took off from then, with postdoc Claire Newland
recruited to analyse the functional effects of the mutations. She
obtained a detailed description of the consequences of the differ-
ent genetic defects on AChR expression and function using patch
and cell recordings from Xenopus oocytes, or from HEK (human
embryonic kidney) 293 cells transfected with the mutant or
wild-type genes. Novel   subunit mutations were identiﬁed and
characterized in the Slow Channel Syndrome (Supplementary ma-
terial B190) and the adult AChR-speciﬁc " subunit gene was found
to be a major target for CMS-associated mutations, probably, as
suggested by Andrew Engel and colleagues, because loss of the "
subunit could be partially compensated by maintaining expression
of foetal AChR (that has the   subunit instead of "). The gene
mutations were located throughout the length of the " subunit
coding sequence, and along with the ﬁrst identiﬁcation of AChR
promoter sequence mutations, were shown to cause reduced
AChR expression and thus underlie AChR deﬁciency syndromes
(Supplementary materials B216, B227 and B239).
However, AChR " mutations did not explain all of the patients
with reduced endplate AChR expression, and mutations in rapsyn,
the protein that anchors AChRs at the neuromuscular junction,
were also identiﬁed (Ohno et al., 2002). Between them these
two gene targets were mutated in many patients with CMS and
each was systematically characterized in vitro (Supplementary ma-
terial B245; Ealing et al., 2002; Cossins et al., 2006). Georgina
Burke, working in the clinic with JND, was able to identify differ-
ent clinical phenotypes in these two forms of AChR deﬁciency
with respect to ophthalmoplegia, arthrogryposis, squint and ap-
noeas, enabling targeted gene screening (Supplementary material
B256).
Shortly before JND’s retirement, Jackie Palace began to take
over the clinical care of the patients, and JND helped to establish
Oxford as the CMS hub of a National Commissioning Group
(NHS) for rare neuromuscular disorders (with Kate Bushby in
Newcastle and Mike Hanna and Francesco Muntoni in London),
which he directed until 2007. The clinical and experimental work
has ﬂourished with the important identiﬁcation of limb-girdle
myasthenic syndrome associated with mutations in the
recently-discovered DOK7 gene, the clinical correlates
(Supplementary materials B67 and B275), and the realisation
that treatment with ephedrine or other b-2 adrenergic receptor
agonists such as salbutamol can lead to dramatic patient improve-
ments in this now commonly recognized CMS (Lashley et al.,
2010). Indeed, a greater understanding of the genetics and mo-
lecular mechanisms underlying CMS means that treatments can
now be tailored to the different forms, all of which show at
least a partial response to the appropriate drugs. Thus,
anti-cholinesterases, 3,4-diaminopyridine, AChR open-channel
blockers or salbutamol/ephedrine may all be beneﬁcial alone or
in combination depending on the syndrome (see also Engel
et al., 2010).
Of course, the hope is as always for a more speciﬁc therapy.
John Ealing, MRC clinical training fellow, joined the group to show
that DNA hammerhead ribozymes could be used to repair or
change AChR gene sequences (in collaboration with Professor
Matthew Wood, Oxford), and had considerable success in vitro.
But for further studies animal models have been created and stu-
died electrophysiologically by postdocs Judith Cossins and Richard
Webster for AChR deﬁciency (Cossins et al., 2004) or the slow
channel syndrome (Webster et al., 2010), so that now potential
drug or genetic therapies can be suitably trialled experimentally.
Lambert Eaton myasthenic syndrome
One of JND’s talents was to recognize an autoimmune disease on
the basis of clinical hints—not unlike the autoimmune associations
in patients with myasthenia and/or their relatives that ﬁrst con-
vinced Iain Simpson that myasthenia gravis was mediated by anti-
bodies (Simpson, 1960). In the early 1980s, JND started to see
patients with the Lambert Eaton myasthenic syndrome, which is
often associated with small cell lung cancer. First characterized
by Eaton and Lambert (1957), it was associated with a marked
decrease in the presynaptic release of the acetylcholine packets
(Elmqvist et al., 1968; Lambert and Elmqvist, 1971). Indeed
Nick Murray and JND had begun to treat patients with
4-aminopyridine, a drug that increases acetylcholine release but
resulted quite frequently in seizures or other CNS disturbances
(Supplementary material B35); with Jackie Palace, JND later popu-
larized 3,4-diaminopyridine for both CMS and Lambert Eaton
myasthenic syndrome.
Back then, the cause of Lambert Eaton myasthenic syndrome
was unknown; paraneoplastic aetiologies were only just beginning
to be studied in detail and some held cancer-related neurotoxic
factors responsible for reducing transmitter release (Lambert and
Lennon, 1982), although an immune basis was also suggested
(Lennon et al., 1982), and had been for the non-tumour cases
(Gutmann et al., 1972). On a speculative basis, JND
plasma-exchanged three patients (Supplementary material B33).
All showed relatively short-lived clinical improvements, which
took 15–20 days to reach maximum (versus 3–5 days in myasthe-
nia gravis). That encouraged him to start using prednisolone and
azathioprine, achieving a remarkable improvement and successive
increase in the muscle action potential in one patient
(Supplementary material B33).
These successes clearly supported the idea that Lambert Eaton
myasthenic syndrome was antibody-mediated, but the offending
factor could still have been a biologically active peptide or other
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To justify the effort needed to identify the target and establish an
antibody test, it was important to show that IgG antibodies were
involved. Bethan Lang was cajoled into injecting 10mg of puriﬁed
Lambert Eaton myasthenic syndrome IgG intraperitoneally into
mice every day (including weekends) for 37–77 days! The quantal
content of neuromuscular transmission studied by Dennis Wray
was signiﬁcantly reduced in all test animals versus controls, but
with no effect on miniature endplate potential amplitudes or AChR
numbers (Supplementary material B33), strongly indicating that
the presynaptic defects in patients were IgG-mediated.
These ﬁndings stimulated many studies in Lambert Eaton
myasthenic syndrome; Peter Molenaar showed that acetylcholine
contents of Lambert Eaton myasthenic syndrome muscle were
normal, but conﬁrmed that the release was deﬁcient
(Supplementary material B42), as also found in the mouse model
(Supplementary material B60). And further passive transfer experi-
ments detailed the reduction in quantal content at rest, and the
lack of decrement (increments were rare in the mice) during re-
petitive trains at high frequencies (Supplementary material B48). In
fact, the effects developed over the ﬁrst few days, declined in
parallel with falling human IgG levels after injections ceased, and
were independent of mouse complement (Supplementary material
B68). They clearly involved the voltage-gated calcium channel,
since the calcium-dependency of AChR release was reduced at
all calcium concentrations, and both nerve-evoked and high K
+-
induced acetylcholine release were inhibited (Supplementary ma-
terial B87). These experiments were paralleled by a very successful
collaboration between JND and Dr Andrew Engel at the Mayo
Clinic whereby mouse diaphragms were ﬁxed and sent to
Minnesota, USA for freeze fracture and electron microscopy.
Engel and a succession of his visiting Japanese clinical fellows
demonstrated beautifully the normal clustering of the presynaptic
active zone particles that are voltage-gated calcium channels,
and their disorganization/disappearance over time, indicating
internalization and destruction of the protein—analogous to the
antigenic modulation shown earlier in myasthenia gravis—which
correlated with the electrophysiological defects seen in Oxford
(Supplementary materials B47, B84, B85, B86, B104 and B110).
To prove that this was also caused by divalent antibodies
cross-linking the target protein (calcium channels assumed),
monovalent Fab fragments did not achieve the same effect
(Supplementary material B128). Meanwhile, an association with
HLA DR3-B8 had been found in Lambert Eaton myasthenic syn-
drome (Supplementary material B76; later conﬁrmed by Wirtz
et al., 2005), and Stephanie Robb and postdoc Terence Bowley
had used the newly acquired and much prized Fluorescence
Activated Cell Sorting machine to follow lymphocyte subsets
during treatment (Supplementary material B70).
By the mid-1980s, the race was on to conﬁrm that the antibo-
dies were indeed directed against voltage-gated calcium channels
and to establish an assay that could be used for diagnosis. Bethan
Lang and her colleagues turned to studying cell lines that ex-
pressed the channels. A breakthrough was when medical student
Victor Tse and Andy Roberts showed that the IgG from patients
inhibited the K
+-induced calcium inﬂux into cell lines derived from
small cell lung cancers—the cancers most strongly associated with
Lambert Eaton myasthenic syndrome—indicating for the ﬁrst time
a direct relationship between the antibodies and these tumours,
and published in Nature (Supplementary material B72). Indeed,
small-cell lung cancer patients with Lambert Eaton myasthenic
syndrome appear to survive better than those without the auto-
immune disease as later shown by Paul Maddison (Supplementary
material B223). The inhibition of calcium inﬂux correlated with
disease severity (Supplementary material B113); in the rodent
neuroblastoma/glioma cell line NG108, it appeared to be targeting
L-type calcium channels (Supplementary material B128). But it
took the discovery of cone snail neurotoxins by Oliviera and col-
leagues (1987) to provide the tools needed for distinguishing the
different calcium channel subtypes and identifying the true target
for the Lambert Eaton myasthenic syndrome antibodies. In 1989,
Sher and colleagues (1998) reported the ﬁrst positive results of
immunoprecipitation of
125I-conotoxin GVIA-labelled N-type
voltage-gated calcium channels, demonstrating the antibodies in
 40% of patients with Lambert Eaton myasthenic syndrome; simi-
lar results were reported for 36 patients from Oxford
(Supplementary material B131).
This was encouraging but evidence was accruing that another
toxin was required, since the GVIA conotoxin did not inhibit cal-
cium channels at the neuromuscular junction. It was not until 1995
that visiting clinical fellow Masakatsu Motomura showed that
voltage-gated calcium channel antibodies are present in 485%
of patients with Lambert Eaton myasthenic syndrome using
the MVIIC conotoxin to label the appropriate (P/Q-type)
voltage-gated calcium channel (Supplementary material B177
and Lennon et al., 1995). These antibodies were found in para-
neoplastic and other Lambert Eaton myasthenic syndrome patients
and not in disease control groups, but also in a few with small cell
lung cancer without evident Lambert Eaton myasthenic syndrome.
Within patients, they correlated well with clinical state during
treatments. It was still not altogether clear how speciﬁc the anti-
bodies were for the P/Q-type (MVIIC-binding) voltage-gated
calcium channels, or whether other antibodies were involved; sev-
eral studies in collaboration with other groups looked further at
antibody speciﬁcities in paraneoplastic and non-paraneoplastic pa-
tients (Supplementary materials B195, B214, B152, B171 and
B175).
A seminal review of 50 cases (Supplementary material B106) by
JND with John O’Neill and Nick Murray highlighted the autonomic
dysfunction that is often evident, but not always appreciated, in
these patients (and was probably the explanation for the urinary
retention that Bethan Lang found in a few of her injected mice).
A visiting Nufﬁeld Fellow from Melbourne, Sally Waterman,
undertook a detailed study of the calcium channels mediating
transmitter release at autonomic post-ganglionic synapses; all
types of voltage-gated calcium channel were involved, albeit to
different extents and mainly during high frequency stimulation
(which is relevant to in vivo function) (Waterman, 1996). When
the mice were given Lambert Eaton myasthenic syndrome IgG,
not only were the P-type channels selectively decreased but
other voltage-gated calcium channels were upregulated, implying
compensatory mechanisms (Supplementary material B201), as pre-
viously shown in myasthenia gravis. In collaboration with Eli Lilly,
clinical fellow Ashwin Pinto explored the effects of Lambert Eaton
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channel subtypes, in stably transfected HEK cells, and found a
marked reduction in P-type voltage-gated calcium channel, with
little effect on any of the other subtypes examined. When the
same IgG preparations were applied to cerebellar granular cells
in culture, however, the electrophysiological responses became
less dependent on P/Q-type voltage-gated calcium channels,
with an increase in the contributions of other voltage-gated cal-
cium channels (Supplementary material B213). Bethan Lang’s fur-
ther work conﬁrmed a similar upregulation of calcium channel
subtypes at the mouse neuromuscular junction after injection of
Lambert Eaton myasthenic syndrome IgG (Giovannini et al.,
2002).
Seronegative myasthenia gravis
It was clear from the earliest days that 10–20% of patients with
generalized myasthenia gravis did not have detectable serum
AChR antibodies by the radioimmunoprecipitation assay, as origin-
ally mentioned by Lindstrom et al. (1976). In fact symptoms were
often rather severe, involving bulbar and respiratory muscles, but
the patients usually responded extremely well to plasma ex-
change—which JND used almost as a ‘diagnostic tool’ for distin-
guishing autoimmune from potentially genetic disorders—although
they were often relatively resistant to pyridostigmine or conven-
tional immunotherapies. Thymectomy did not seem to be helpful,
and their thymuses showed only mild thymic changes
(Supplementary material B139). Stuart Mossman, a visiting clinical
fellow, undertook the ﬁrst passive transfer experiments, using IgG
prepared from plasma exchange samples and demonstrating a
defect in nerve-evoked muscle responses in the injected mice
with little effect on AChR numbers (Supplementary material
B79). This suggested that seronegative myasthenia gravis IgG
might also be targeting the presynaptic terminals, which indeed
showed mild but still unexplained abnormalities in some mice, as
demonstrated later in more detailed in vitro studies by PhD stu-
dent, Judith Burges, with Dennis Wray (Supplementary material
B161). They found reduced quantal contents with some seronega-
tive myasthenia gravis IgG preparations, as well as reduced mini-
ature endplate potential amplitudes, and conﬁrmed the minimal
change in AChR numbers. Several studies over subsequent years
aimed to identify an antibody and its target in these patients, but
the results were not conclusive. Serum reduced AChR function in
cultured cell lines, often within a few minutes. This effect was
reversible when the antibody was washed out, and appeared to
be IgM rather than IgG (Supplementary materials B140 and B159;
Spreadbury et al., 2004)—and yet the passive transfer experi-
ments had been conducted with IgG not IgM!
The ﬁeld needed a new approach, and in 2000, following a
meeting in Mossbach, Germany, with Werner Hoch, an independ-
ent investigator at the Max Planck Institute for Neurobiology in
Tu ¨bingen (who died suddenly in 2006), clinical fellow John
McConville and Hoch quickly identiﬁed IgG antibodies to muscle
speciﬁc kinase in many of the patients with seronegative myasthe-
nia gravis who had previously responded to plasma exchange
(Supplementary material B235). These antibodies were present in
the plasmas that had been used for passive transfer experiments
(mainly from patients with severe bulbar myasthenia gravis), and
did not correlate with the IgM-mediated reduction in AChR func-
tion (Plested et al., 2002). In fact, IgG from patients with muscle
speciﬁc kinase antibodies did not directly affect AChR function
in vitro. The target and mechanisms involved in the latter phe-
nomenon remain unclear—as does the exact mechanism of action
of the muscle speciﬁc kinase antibodies, which is being explored in
animal models (S. Viegas et al., in preparation).
A ﬁtting tribute to JND’s policy of building a multidisciplinary
team was when clinical fellow, Isabel Leite, used co-transfected
rapsyn to cluster AChR naturally on the surface of human embry-
onic kidney cells; about half of the previous negative patients were
clearly positive for binding to the AChR under these conditions,
probably because the high density of AChRs allowed the antibo-
dies to bind divalently. Interestingly, these patients had more
thymic changes than those who did not show this reactivity
(Leite et al., 2008), suggesting that the aetiological and pathogen-
ic mechanisms may be similar to those of typical AChR antibody-
positive myasthenia gravis, a ﬁnding conﬁrmed in animal models
(S. Jacob et al., in preparation).
Peripheral neuropathies and acquired
neuromyotonia
In the 1990s with experimental work on Lambert Eaton myasthe-
nic syndrome beginning to slow down, JND enjoyed a brief so-
journ among the gangliosides in collaboration with Professor Hugh
Willison in Glasgow. They showed that the neuromuscular junction
could also be used to study those antibodies (Supplementary ma-
terials B169 and B180), leading to much more detailed investiga-
tions by Willison and his collaborators, including Peter Molenaar’s
former colleague Jaap Plomp.
But JND’s main new focus at this time was acquired neuromyo-
tonia. This condition was probably ﬁrst documented by A. Morvan
as 9 of the 10 cases he described as ‘chore ´e ﬁbrillaire’ did not
have the CNS involvement that is now associated with ‘Morvan’s
syndrome’ (Morvan, 1890). Again it was the combination of oc-
casional tumours (thymomas), other autoimmune associations, and
a few reports of precipitation by penicillamine treatment, that
drew JND’s attention to a possible autoimmune aetiology (re-
viewed with Kerry Mills, Supplementary material B153). The ﬁrst
patient he saw with this condition was a retired Greek colonel
(ANA, Supplementary material C) who responded to plasma ex-
change with a dramatic reduction in the typical neuromyotonic
discharges recorded by Kerry Mills. Further clinical studies resulted
and another antibody-mediated disease was proposed.
The laboratory work followed the now familiar pattern of pas-
sive transfer of IgG to mice to demonstrate that there were patho-
genic antibodies. This was accomplished by a medical student
Sourab Sinha (Supplementary material B136), and followed up
later by visiting paediatrician Paul Shillito who investigated the
neuromuscular junctions in more detail. Although in vitro results
using neuronal cell lines were not conclusive, everything pointed
to involvement of a potassium channel, and an immunoprecipita-
tion assay was set up by PhD student Katherine Leys with radio-
active dendrotoxin to label detergent extracts of brain
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to that used for voltage-gated calcium channel antibodies in
Lambert Eaton myasthenic syndrome, but was less successful,
with only a proportion of plasma exchange-responsive patients
proving to be positive with this test and usually with rather low
titres, many not very different from the control range
(Supplementary material B182). Nevertheless, Shillito’s in vitro stu-
dies on ﬁve patients’ IgGs, and those of Peter Molenaar and col-
leagues in Leiden, supported the idea that voltage-gated
potassium channel antibodies were the pathogenic target
(Supplementary material B182). But to increase sensitivity, another
approach was needed, and MRC clinician scientist Ian Hart, who
JND had recruited to Oxford after his PhD with Professor Martin
Raff at UCL, developed an indirect immunohistochemical assay
using Xenopus oocytes that he had injected with messenger
RNAs for the different voltage-gated potassium channel subunits
(Supplementary material B193). This proved somewhat more sen-
sitive and showed that the antibodies were heterogeneous in their
speciﬁcity for the different dendrotoxin-binding voltage-gated po-
tassium channel subunits.
JND with Ian Hart (who died suddenly in 2008), Paul Maddison
and Kerry Mills (who moved to a Chair at King’s College) put
together an impressive clinical and neurophysiological description
of the disease in 67 patients with ‘peripheral nerve hyperexcitabil-
ity’ (a more accurate description than ‘neuromyotonia’), including
patients with cramp fasciculation syndrome who shared similarities
(Supplementary material B240). But the serology was always dis-
appointing in patients with neuromyotonia. However, the high
levels in a patient with Morvan’s syndrome who made a substan-
tial recovery with plasma exchange, and a chance conversation
with Joel Oger (neurologist in Vancouver) led to the appreciation
that such antibodies were also present in patients with CNS dis-
ease, including limbic encephalitis (Buckley et al., 2001). Only in
the last few years has it become clear that the antibodies are not
mainly directed against the voltage-gated potassium channels
themselves in these patients, but against other proteins that are
complexed with the voltage-gated potassium channels in brain
tissue (Irani et al., 2010; Lai et al., 2010).
John Newsom-Davis as
clinician
Although JND’s excitement seemed to stem mostly from labora-
tory work, he did not neglect clinical studies and he encouraged
the work of those young clinicians who were more suited to ‘dry’
rather than ‘wet’ research, particularly if they could lead to a
better understanding of the diseases that he had helped to deﬁne.
In the early days at Queen Square, he was a major collaborator
on Richard Hughes’ highly cited trials of plasma exchange in
Guillain–Barre ´ syndrome (Supplementary materials B16 and B40),
and involved in a number of signiﬁcant case reports including
rabies encephalitis (Supplementary material B12), one of the ﬁrst
cases of Creutzfeldt–Jakob disease after growth hormone
(Supplementary material B67), and head injury in boxers
(Supplementary material B7). From then, apart from a continued
interest in respiratory function in different diseases (Supplementary
materials B24, B25, B114, B126 and B145), most of his focus was
on neuromuscular junction disorders. While still at Queen Square,
and later in Oxford, JND twice asked whether there were central
cholinergic functional effects in myasthenia gravis or following
treatment (Supplementary materials B115 and B186)—there
weren’t. But his most productive interactions were with the neuro-
physiologists. With Nick Murray he investigated the use of
4-aminopyridine and documented the response to plasma ex-
change in the Lambert Eaton syndrome (Supplementary materials
B35and B61). Then, as mentioned above, with John O’Neill,
Murray and JND reviewed in detail the clinical and physiological
aspects of 50 cases of Lambert Eaton myasthenic syndrome, which
remains the most cited and comprehensive account of the disease
(Supplementary material B106). Work on this condition was con-
tinued by JND’s visiting fellows and registrars. Giles Elrington per-
formed one of the ﬁrst systematic studies of paraneoplastic
disorders in patients with small cell lung cancer (Supplementary
material B130), although Lambert Eaton myasthenic syndrome
was not a common association (Supplementary material B284);
Peter Bain showed the effectiveness of intravenous immunoglobu-
lin in a cross-over study (Supplementary material B183); Colin
Chalk demonstrated the response of Lambert Eaton myasthenic
syndrome to treatment of the associated small cell lung cancer
(Supplementary material B122); and Paul Maddison, conversely,
showed a better outcome for the small cell lung cancer in patients
with Lambert Eaton myasthenic syndrome (Supplementary mater-
ial B236). Paul Maddison, with Kerry Mills, also detailed the
neurophysiology of Lambert Eaton myasthenic syndrome
(Supplementary materials B205, B206 and B207), and later of
neuromyotonia (Supplementary materials B222 and B271) and
Maddison and JND wrote two valuable Cochrane Reviews of
treatment (Supplementary materials B248 and B263).
Jackie Palace, initially splitting her time between the laboratory
and the clinic, conducted two important studies with JND—the
effects of 3,4-diaminopyridine in congenital forms of myasthenia
(Supplementary material B135) and the key trial of azathioprine as
a steroid-sparing agent in myasthenia gravis (Supplementary ma-
terial B212). The clinical features of patients with CMS that David
Beeson identiﬁed, including many with Dok-7 mutations, were
characterized (Supplementary material B275), and Georgina
Burke documented useful clinical clues to the diagnoses of AChR
and rapsyn deﬁciencies (Supplementary materials B246 and B256).
The discovery of muscle speciﬁc kinase antibodies provided oppor-
tunities for a new look at patients without AChR antibodies; Maria
Farrugia working with Robin Kennett, JND and Professor Paul
Matthews showed the distinctive electrophysiological and muscle
imaging features of this disease (Supplementary materials B268,
B269 and B273).
JND provided useful treatment algorithms for diseases he stu-
died (e.g. Supplementary material B210). Use of treatments such
as steroids, intravenous immunoglobulin and thymectomy pro-
vided not only food for thought but also some headaches.
Steroids could cause myopathies (Supplementary material B154),
intravenous immunoglobulin was useful but mechanisms were un-
clear and sometimes there were serious and unpredictable
side-effects (Supplementary materials B156 and B244), and the
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tested. After his retirement, despite a little more time with his
family, JND switched focus to clinical trials in a characteristically
effective manner, helping to promote better and more compre-
hensive reporting of their results (Supplementary material B242)
and establishing with US colleagues Gil Wolfe, Henry Kaminski,
Fred Jaretski and Gary Cutter, among others, the ﬁrst blinded
randomized clinical trial of thymectomy in myasthenia gravis
which is still recruiting today (Supplementary materials B254,
B276, B280 and H).
Epilogue
The achievements of JND and the scientists and clinicians who
worked with him over the 20 years from 1977 to 1998 when
he retired, were focused on a small anatomical structure and a
relatively rare set of neurological diseases, but they had substantial
implications for the recognition and treatment of
immune-mediated disorders as recognized by election to
Fellowship of the Royal Society in 1991 (Fig. 4A). JND would
have been the ﬁrst to admit that being in the right place at the
right time, and able to attract talented, hard-working and loyal
people, were all crucial for his success. Having said that, his ex-
ceptional ability was to be fully involved with the laboratory re-
search—indeed clearly happiest when, changed into his corduroys
and a sweater, he was at his desk or chatting by a laboratory
bench in the Institute of Molecular Medicine (now Weatherall
Institute of Molecular Medicine). Moreover, unlike some in his
position, he took co-authorship seriously, always making time to
read drafts carefully, and making constructive suggestions—or
indicating the need for reconstruction! He also had the integrity
to opt out when he had not contributed substantially.
Over that time, he played a key part in both the clinical and
research training of over 30 neurologists (see for instance Buckley;
Supplementary material I), not only from Britain and its
Commonwealth but also from Europe and the Far East. As Guy
Chauplannaz from Lyons, France, wrote following JND’s death,
‘John was a truly European scientist. Dealing with rare diseases,
he understood that co-operation with teams outside the UK could
bring success sooner. He developed such friendly co-operations
with warmth and efﬁcacy’. Indeed, JND was loved and greatly
respected by innumerable patients (Burrow; Supplementary mater-
ial J). Many were especially grateful for his thoughtful and egali-
tarian attention when adapting their management to suit their
particular needs; also for giving them the courage to keep ﬁghting
their myasthenia gravis—even though, as he often said, it would
be ‘a marathon and not a sprint’—and sometimes urging them to
go ahead and have children, despite previous advice to the con-
trary (N. Willcox, personal communication and Supplementary
material K) ‘It is also impossible to overstate John’s contributions
to the evolution of medical care and research at Oxford in his role
as a top-class clinical scientist and clinical neurologist. With his
delightful, ever-youthful personality he was a wonderful colleague
and much beloved by his students and all those who worked for
him during his remarkable career’ (Sir David Weatherall).
His sudden death while visiting Romania shocked neurologists
throughout the world but his legacies—ongoing neuroimmunolo-
gical and genetic research in Oxford, a generation of neurologists
who acknowledge his many contributions to the discipline and to
their own careers, the International Thymectomy Trial, and the
rooms at the Academy of Medical Sciences that were recently
named in his memory—are only a few of those that bear witness
to his immense intellectual abilities and personal qualities. But even
his closest colleagues did not appreciate the full extent of his con-
tributions, both professional and personal until, following his
death, the tributes and recollections began to ﬂow in from patients
and doctors all over the world.
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